Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: The potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation

Hsuan Ying Huang, Robert B. West, Ching Cherng Tzeng, Matt Van De Rijn, Jun Wen Wang, Shih Cheng Chou, Wen Wei Huang, Hock Liew Eng, Ching Nan Lin, Shih Chen Yu, Jing Mei Wu, Chiu Chin Lu, Chien Feng Li

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Diffuse-type tenosynovial giant cell tumor (D-TSGCT) is an aggressive proliferation of synovial-like mononuclear cells with inflammatory infiltrates. Despite the COL6A3-CSF1 gene fusion discovered in benign lesions, molecular aberrations of malignant D-TSGCTs remain unidentified. Experimental Design: We used fluorescent in situ hybridization and in situ hybridization to evaluate CSF1 translocation and mRNA expression in six malignant D-TSGCTs, which were further immunohistochemically compared with 24 benign cases for cell cycle regulators involving G1 phase and G1-S transition. Comparative genomic hybridization, real-time reverse transcription-PCR, and a combination of laser microdissection and sequencing were adopted to assess chromosomal imbalances, cyclin A expression, and TP53 gene, respectively. Results: Five of six malignant D-TSGCTs displayed CSF1 mRNA expression by in situ hybridization, despite only one having CSF1 translocation. Cyclin A (P = 0.008) and P53 (P < 0.001) could distinguish malignant from benign lesions without overlaps in labeling indices. Cyclin A transcripts were more abundant in malignant D-TSGCTs (P < 0.001). All malignant cases revealed a wild-type TP53 gene, which was validated by an antibody specifically against wild-type P53 protein. Chromosomal imbalances were only detected in malignant D-TSGCTs, with DNA losses predominating over gains. Notably, -15q was recurrently identified in five malignant D-TSGCTs, four of which showed a minimal overlapping deletion at 15q22-24. Conclusions: Deregulated CFS1 overexpression is frequent in malignant D-TSGCTs. The sarcomatous transformation involves aberrations of cyclin A, P53, and chromosome arm 15q. Cyclin A mRNA is up-regulated in malignant D-TSGCTs. Non - random losses at 15q22-24 suggest candidate tumor suppressor gene(s) in this region. However, P53 overexpression is likely caused by alternative mechanisms rather than mutations in hotspot exons.

Original languageEnglish
Pages (from-to)6023-6032
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number19
DOIs
Publication statusPublished - 2008 Oct 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: The potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation'. Together they form a unique fingerprint.

  • Cite this

    Huang, H. Y., West, R. B., Tzeng, C. C., Van De Rijn, M., Wang, J. W., Chou, S. C., Huang, W. W., Eng, H. L., Lin, C. N., Yu, S. C., Wu, J. M., Lu, C. C., & Li, C. F. (2008). Immunohistochemical and biogenetic features of diffuse-type tenosynovial giant cell tumors: The potential roles of cyclin A, P53, and deletion of 15q in sarcomatous transformation. Clinical Cancer Research, 14(19), 6023-6032. https://doi.org/10.1158/1078-0432.CCR-08-0252